Get the Stockscreener App
0.6653
4.96%
-0.0347
After Hours:
.66
-0.0053
-0.80%
Mersana Therapeutics Inc Stock (MRSN) Latest News
What is William Blair’s Forecast for MRSN FY2024 Earnings? - Defense World
SG Americas Securities LLC Purchases 25,058 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
What is Mersana Therapeutics Inc (MRSN) Stock Return on Shareholders’ Capital? - SETE News
Mersana Therapeutics Inc (MRSN) Stock: Analyzing the Quarterly Movement - The News Heater
Mersana initiated at outperform at William Blair on antibody-drug conjugate potential - MSN
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Insider Alert: Mersana's Latest Stock Compensation Move Reveals Strategic Hiring Push - StockTitan
Mersana Therapeutics Posts Updated Corporate Presentation on Company Website - Armenian Reporter
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation - MSN
William Blair starts Mersana stock with Outperform rating By Investing.com - Investing.com South Africa
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
William Blair starts Mersana stock with Outperform rating - MSN
Mersana Therapeutics Inc [MRSN] Shares Rise 18.66 % on Wednesday - Knox Daily
Mersana Therapeutics Updates Investor Presentation Online - TipRanks
Investors in cash trouble should check out Mersana Therapeutics Inc (MRSN) - SETE News
MRSNMersana Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Exclusive: Mersana Therapeutics CEO to Reveal ADC Pipeline Updates at Guggenheim Conference - StockTitan
Apple Swings to Outperformer: Is It a Buy Ahead of Earnings? - The Globe and Mail
MRSN News Today | Why did Mersana Therapeutics stock go down today? - MarketBeat
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) PT at $5.57 - MarketBeat
MRSN stock touches 52-week low at $0.56 amid market challenges - MSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Average Price Target from Analysts - MarketBeat
MRSN stock touches 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa
Mersana Therapeutics' SVP sells shares worth $4,912 - MSN
Mersana Therapeutics chief development officer sells shares worth $3,444 - MSN
Mersana Therapeutics CEO sells $2,618 in stock - MSN
Mersana Therapeutics' chief accounting officer sells shares worth $2,061 - MSN
Mersana Therapeutics officer Timothy Lowinger sells $4,667 in stock - MSN
Mersana Therapeutics officer Timothy Lowinger sells $4,667 in stock By Investing.com - Investing.com South Africa
Mersana Therapeutics SVP sells $2,955 in stock By Investing.com - Investing.com South Africa
Mersana Therapeutics' chief accounting officer sells shares worth $2,061 By Investing.com - Investing.com Australia
Mersana Therapeutics CEO sells $2,618 in stock By Investing.com - Investing.com Australia
Mersana Therapeutics' SVP sells shares worth $4,912 By Investing.com - Investing.com South Africa
Mersana Therapeutics SVP sells $2,955 in stock - MSN
Mersana therapeutics VP Mandelia sells $1,128 in stock - MSN
Mersana therapeutics' chief officer sells shares worth $1,130 - MSN
JPMorgan Chase & Co. Grows Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana therapeutics director Anna Protopapas sells shares worth $5,009 - MSN
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):